

The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies

Adam J. Fein, Ph.D.

Pembroke Consulting, Inc., and
Drug Channels Institute

January 2016

Full report available for download at

http://drugchannelsinstitute.com/products/industry_report/pharmacy/



COPYRIGHT

Copyright © 2016 by Pembroke Consulting, Inc. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

There are four license term options for *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies*:

<input type="checkbox"/>	Single User License: This license allows for use of this report by one individual person. This person may use the report on any computer, and may print out the report, but may not share the report with any other person or persons. Unless a Department/Team or Corporate License is purchased, a Single User License must be purchased for every person who wishes to use the report within the same organization or enterprise. Buyers who infringe upon these license terms are liable for a Department/Team or Corporate License fee.
<input type="checkbox"/>	Department/Team License: This license allows for use of this report by up to 10 (ten) employees within the same organization or enterprise as the purchaser identified in the upper left corner of this page. Each of these employees may use the report on any computer, and may print out the report, but may not share the report with any other person or persons unless a Corporate License is purchased. Buyers who infringe upon these license terms are liable for a Corporate License fee.
<input type="checkbox"/>	Corporate License: This license allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide as the purchaser identified in the upper left corner of this page. Each of the employees within this organization or enterprise may use the report on any computer, and may print out the report, but may not share the report with any other person or persons outside the enterprise or organization.
<input type="checkbox"/>	Corporate License + Exhibits: This license has the same terms as the Corporate License and includes a PowerPoint file with images of all exhibits in the report. These exhibits can be used under the same terms and conditions as the report can be used.

The complete End User License Agreement is available at:

<http://drugchannelsinstitute.com/files/pharmacyEULA-2016.pdf>

ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke's Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.



Dr. Fein is one of the country's foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein's insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein's popular and influential Drug Channels website (www.DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as *The Wall Street Journal*, *The New York Times*, *USA Today*, *Pharmaceutical Executive*, and many others. He serves on the editorial advisory boards of *Pharmaceutical Commerce* and *Drug Benefit News*.

Dr. Fein earned his Ph.D. from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information

Adam J. Fein, Ph.D.
Pembroke Consulting, Inc.
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.PembrokeConsulting.com
Email: afein@pembrokeconsulting.com

Visit the Drug Channels website for the latest industry updates!



DRUG CHANNELS

Expert Insights on Pharmaceutical Economics
and the Drug Distribution System

www.DrugChannels.net

ABOUT DRUG CHANNELS INSTITUTE

[Drug Channels Institute \(DCI\)](#), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education and computer-based training for and about the pharmaceutical industry.



Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies*—into online e-learning modules that offer a thorough grounding in crucial industry topics, all in 45 minutes or less.

These online learning tools mix the latest industry data and cutting-edge analysis with highly interactive elements that engage and entertain. They educate a wide variety of learners: from sales reps and field teams—who need immediate, easily digestible industry concepts for their key accounts—to internal teams who need to better understand customers and channels.

View a module list at <http://drugchannelsinstitute.com/products/e-learning-modules/>.

View a sample at <http://drugchannelsinstitute.com/e-learning-module-sample/>.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com



INTRODUCTION AND GUIDE TO THIS REPORT

In 2015, amid significant growth, the \$364 billion pharmacy industry began to transform its fundamental structure. Healthcare reform, for instance, is reshaping drug benefits but remains politically contentious. Specialty drugs and specialty pharmacies are booming, as the generic dispensing rate plateaus. Meanwhile, major mergers and acquisitions among pharmacies, health plans, and PBMs will leave the industry more consolidated than ever before. Given these and other changes, understanding the implications of the industry's evolution is crucial.

The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies—our seventh edition—remains the most up-to-date, comprehensive, fact-based analysis of the pharmacy channel and its interactions with other participants in our healthcare system. I have synthesized a wealth of statistical data, research studies, financial information, and my own unique business consulting experience into a definitive, nonpartisan resource.

This report is your ultimate guide to the complex web of interactions within the pharmacy distribution and reimbursement system. It helps pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, benefit managers, managed care executives, healthcare policy analysts, investors, consultants—anyone who wants to understand and benefit from this ever-changing industry.

About the Report

Thousands of companies operate in the U.S. pharmacy distribution and reimbursement system, ultimately enabling more than five billion equivalent prescriptions to be dispensed and paid. The table below highlights the major public companies operating in the pharmacy distribution and reimbursement system. The 2016 edition of this report contains the latest financial and industry data about the strategies and market positions of the largest public companies: CVS Health, Express Scripts, Rite Aid, Walgreens Boots Alliance, OptumRx, Walmart, and others.

Major Public Companies Operating in Pharmacy Drug Channels

Company	Stock Ticker	Primary U.S. Role
CVS Health	CVS	Chain Drugstore/Pharmacy Benefit Manager
Diplomat Pharmacy	DPLO	Specialty Pharmacy
Rite Aid Corporation*	RAD	Chain Drugstore/Pharmacy Benefit Manager
Walgreens Boots Alliance	WBA	Chain Drugstore
Walmart Stores, Inc.	WMT	Mass merchant with pharmacy
AmerisourceBergen Corp.	ABC	Pharmaceutical Wholesaler
Cardinal Health, Inc.	CAH	Pharmaceutical Wholesaler
McKesson Corporation	MCK	Pharmaceutical Wholesaler
Express Scripts, Inc.	ESRX	Pharmacy Benefit Manager/Mail & Specialty Pharmacy
OptumRx (UnitedHealth Group)	UNH	Pharmacy Benefit Manager/Mail & Specialty Pharmacy

* In October 2015, Walgreens Boots Alliance announced its acquisition of Rite Aid.
Source: Pembroke Consulting research

This complex system, illustrated below, contains three key channel flows that we discuss in *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies*:

- **Product movement**, which traces bulk shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. A pharmacy marks the final step in which a prescription is dispensed to a patient.
- **Financial flows**, which transfer money from third-party payers to Pharmacy Benefit Managers (PBMs), who in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers in the form of rebates to PBMs, which share a portion of these payments with plan sponsors, reducing net prescription costs. Manufacturers’ rebates to PBMs and other third-party payers do not flow through wholesale or retail channels.
- **Contractual relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs




Chart illustrates flows for **Patient-Administered, Outpatient Brand-Name Drugs**. Please note that this chart is illustrative. It is not intended to be a complete representation of every type of financial, product flow, or contractual relationship in the marketplace. Source: Pembroke Consulting research

Structure of the 2016 Report

To better reflect the changing industry, this year's edition has been completely updated, reorganized, and expanded. Therefore, the chapters and sections do not correspond to those of previous editions. *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies* analyzes the industry in three major sections, comprising ten chapters. In addition to updating all market data and information, this 2016 edition includes many new elements. We have also integrated the trend and outlook material into the main chapters. This provides a more unified analysis of key industry issues.

Section I: The U.S. Pharmacy Industry

- [Chapter 1: Industry Overview](#) (page 2) defines the industry and its regulatory framework, explains different pharmacy industry participants, and quantifies differences among outpatient dispensing formats. [Section 1.3](#) provides an integrated overview of industry trends and crucial topics, with links to relevant sections within the full report.
- [Chapter 2: Pharmacy Industry Market Structure](#) (page 16) analyzes the industry's prescription and revenue growth trends. It identifies the biggest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and the major national companies. This chapter also updates our analysis of retail clinics and pharmacist-provided clinical services, including medication therapy management services.
- [Chapter 3: Specialty Drugs and Specialty Pharmacies](#) (page 41) provides a comprehensive overview of specialty drugs and the pharmacies dispensing these medications. The chapter discusses the various definitions of specialty drugs and specialty pharmacies and summarizes the top specialty therapy classes and average prescription costs. We present our exclusive analysis of national market share for pharmacy-dispensed specialty drugs and provide a competitive analysis of the various organizations that compete to dispense specialty medications. Chapter 3 also reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs.

Section II: Third-Party Payment and Pharmacy Benefits

- [Chapter 4: Payment and Spending for Prescription Drugs](#) (page 68) has been significantly expanded for the 2016 edition. We examine the primary payers for prescription drugs at retail, mail, and specialty pharmacies. Chapter 4 also analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. We also present the outlook for net prescription drug spending, gross spending changes on traditional and specialty drugs, and the future payer mix
- [Chapter 5: Pharmacy Benefit Management](#) (page 82) identifies the PBM industry's key participants, explains the services provided by PBMs to third-party payers, reviews the

crucial role of PBMs in pharmacy economics, describes the relationship between PBMs and pharmacies that participate in a PBM's network, and reviews how Pharmacy Services Administration Organizations (PSAOs) intermediate between retail pharmacies and PBMs. This year's edition also includes new material on how payers compensate PBMs for benefit management services.

- [Chapter 6: Consumer Copayments and Coinsurance](#) (page 103) analyzes the benefit designs and plan structures that determine out-of-pocket spending for the major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We also explore the growth of plans with prescription deductibles and manufacturers' copay offset programs.
- [Chapter 7: Narrow Pharmacy Networks](#) (page 115), which is new for the 2016 edition, analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for retail pharmacies in commercial health plans and Medicare Part D. We also review the use of mail pharmacies as preferred and restricted options. This chapter explores how narrow networks affect pharmacy profits and describes the development of new performance-based narrow networks. We also evaluate payer-defined networks for specialty drug dispensing.

[Section III: Drug Channel Economics](#)

- [Chapter 8: Prescription Reimbursement by Third-Party Payers](#) (page 131) explains the latest formulas and methodologies for computing a pharmacy's revenue from brand-name, generic, and specialty prescriptions. This chapter compares and contrasts traditional list price methods with acquisition cost reimbursement approaches. We also review the economics of mail vs. retail pharmacies for payers and consumers. This chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor's net costs for a prescription.
- [Chapter 9: Relationships with Pharmaceutical Wholesalers](#) (page 152) explores the interactions of pharmacies with their primary suppliers of drugs. It explains wholesalers' channel roles and services, identifies the largest wholesale suppliers, and analyzes wholesalers' role for specialty drugs and specialty pharmacies. This chapter also analyzes wholesalers' changing relationships with retail chains.
- [Chapter 10: Pharmacy and Prescription Profitability](#) (page 178) unites the reimbursement and cost discussion from Chapters 8 and 9 by presenting the latest data on pharmacy and prescription profitability. This section documents overall drugstore profitability, pharmacy margins for prescriptions, profit differences between brand and generic prescriptions, and PBMs' per-prescription profits from network and mail pharmacies. Finally, we consider pharmacy profits in the 340B drug pricing program.

Using the 2016 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are also nearly 400 endnotes, most of which have hyperlinks to original source materials.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: **ALT+Left Arrow**
- Mac: **Command+Left Arrow**

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: **Shift+CTRL+F**
- Mac: **Shift+Command+F**

As always, I welcome your comments and feedback. Please contact me if you have any questions or comments about *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies*.

Adam J. Fein
January 2016

P.S. You can find post-publication errata here:

<http://drugchannelsinstitute.com/files/2016-PharmacyIndustry-errata.pdf>

CONTENTS

SECTION I: THE U.S. PHARMACY INDUSTRY	1
Chapter 1: Industry Overview	2
1.1. Defining the Practice of Pharmacy.....	2
1.1.1. The Products That Pharmacies Dispense	3
1.1.2. Top Traditional Therapy Classes and Average Prescription Costs	4
1.1.3. Pharmacies and the Drug Supply Chain Security Act.....	5
1.2. Pharmacy Industry Participants	6
1.2.1. Outpatient Pharmacy Dispensing Formats	6
1.2.2. Differences Among Outpatient Dispensing Formats	8
1.2.3. Pharmacist Employment and Salaries.....	11
1.3. Pharmacy Industry Trends and Report Overview	13
Chapter 2: Pharmacy Industry Market Structure.....	16
2.1. Industry Trends	16
2.1.1. Total and 30-Day Equivalent Prescriptions	16
2.1.2. Pharmacy Industry Revenues.....	19
2.2. National Market Share by Company	20
2.3. Trends by Dispensing Format.....	21
2.3.1. Revenues, Prescriptions, and Number of Pharmacies: 2010 to 2015 Trends	21
2.3.2. Market Changes in 2015	23
2.3.3. National Retail Chains	25
2.3.4. Regional Drugstore Chains	28
2.3.5. Independent Pharmacies	29
2.3.6. Mail Pharmacies.....	31
2.4. Compensation for Healthcare Services.....	34
2.4.1. Retail Clinics	35
2.4.2. Clinical Services and Medication Therapy Management (MTM).....	37
2.4.3. Immunization	40
Chapter 3: Specialty Drugs and Specialty Pharmacies.....	41
3.1. Specialty Drugs.....	41

3.1.1. Common Characteristics of Specialty Drugs	41
3.1.2. How Payers Define Specialty Drugs	42
3.1.3. Top Specialty Therapy Classes and Average Prescription Costs	44
3.1.4. Specialty’s Share of Pharmacy Benefit Spending.....	45
3.2. Specialty Pharmacies.....	46
3.2.1. Defining Specialty Pharmacy.....	46
3.2.2. Clinical and Data Services	47
3.2.3. Accreditation.....	49
3.2.4. Number of Specialty Pharmacies	49
3.3. Specialty Market Participants	51
3.3.1. Overview	51
3.3.2. Pharmacy Benefit Managers.....	52
3.3.3. Independent Specialty Pharmacies.....	52
3.3.4. Retail Chains.....	54
3.3.5. Hospitals and Health Systems.....	56
3.3.6. Physician Practices	57
3.3.7. Wholesalers.....	58
3.4. National Market Share for Specialty Pharmaceuticals	59
3.5. Mergers and Acquisitions Among Specialty Pharmacies	60
3.6. Manufacturer Channel Strategies for Specialty Drugs.....	62
3.6.1. Manufacturer-Defined Dispensing Networks	62
3.6.2. Specialty Hub Services	64
3.7. The Outlook for Pharmacy-Dispensed Biosimilars.....	65
SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS.....	67
Chapter 4: Payment and Spending for Prescription Drugs	68
4.1. Prescription Drugs and U.S. Healthcare Spending	68
4.2. Recent Payer and Spending Trends	69
4.2.1. Payment for Prescription Drugs in 2014	69
4.2.2. Net Drug Spending in 2014: Payer Trends	71
4.2.3. Gross Drug Spending in 2014: Traditional vs. Specialty.....	73
4.3. The Drug Spending Outlook	75

4.3.1. The Specialty Boom and the Generic Plateau	75
4.3.2. Net Drug Spending Projections to 2024.....	77
4.3.3. Gross Drug Spending Projections: Traditional vs. Specialty.....	78
4.3.4. Payment for U.S. Outpatient Prescription Drugs in 2024	80
Chapter 5: Pharmacy Benefit Management	82
5.1. PBM Industry Structure.....	82
5.2. Relationships Between PBMs and Plan Sponsors	85
5.2.1. PBM Services for Plan Sponsors.....	85
5.2.2. Formulary Development and Management	86
5.2.3. Utilization Management Services by PBMs	87
5.3. Rebate Negotiations with Manufacturers	88
5.3.1. Manufacturer Rebates	88
5.3.2. Formulary Exclusions	91
5.3.3. How Rebates Affect Third-Party Payers.....	93
5.4. Relationships Between PBMs and Pharmacies.....	95
5.4.1. Retail Pharmacy Participation in PBM Networks.....	95
5.4.2. PBM-Pharmacy Negotiations	96
5.4.3. Smaller Pharmacies and Pharmacy Services Administration Organizations.....	97
5.5. PBM Compensation by Plan Sponsors	99
5.5.1. Spread Pricing	101
5.5.2. Pass-Through Pricing.....	101
Chapter 6: Consumer Copayments and Coinsurance	103
6.1. Employer-Sponsored Health Plans.....	103
6.2. Health Insurance Marketplace Plans	105
6.3. Medicare Part D	107
6.4. Medicaid.....	110
6.5. Prescription Drug Deductibles	111
6.6. Manufacturer Copayment Offset Programs	112
Chapter 7: Narrow Pharmacy Networks	115
7.1. Overview of Pharmacy Benefit Network Models.....	115
7.1.1. Network Options.....	115

7.1.2. The Appeal of Narrow Networks	117
7.2. Retail Pharmacy Networks	119
7.2.1. Preferred Retail Networks in Medicare Part D	119
7.2.2. Narrow Retail Networks in Commercial Health Plans	122
7.2.3. Narrow Mail Networks in Commercial and Other Health Plans	124
7.2.4. Pharmacy Profits as the Source of Cost Savings in Narrow Retail Networks.....	125
7.3. The Emergence of Performance-Based Pharmacy Networks	126
7.4. Payer-Defined Specialty Dispensing Networks	127
SECTION III: DRUG CHANNEL ECONOMICS	130
Chapter 8: Prescription Reimbursement by Third-Party Payers.....	131
8.1. The Basics of Prescription Reimbursement	131
8.1.1. Estimated Acquisition Cost (EAC).....	132
8.1.2. Dispensing Fees.....	133
8.1.3. Service and Data Fees	134
8.2. Reimbursement for Brand-Name and Specialty Prescriptions	135
8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices	135
8.2.2. Why List Prices Are Used for Brand-Name Prescription Reimbursement	136
8.2.3. Average AWP Discounts for Pharmacy Reimbursement	137
8.2.4. Retail vs. Mail Reimbursement Rates for Brand-Name Drugs	138
8.2.5. Why Mail Pharmacies Accept Lower Reimbursements	140
8.3. Reimbursement for Generic Prescriptions.....	141
8.3.1. Challenges for List-Price Benchmarks	141
8.3.2. Maximum Allowable Cost (MAC) Limits.....	142
8.3.3. Regulation and Laws Regarding MAC Limits.....	143
8.3.4. Medicaid and Federal Upper Limits	144
8.4. Acquisition Cost Reimbursement.....	145
8.4.1. The AAC and NADAC Benchmarks	145
8.4.2. Adoption of Acquisition Cost by State Medicaid Programs.....	147
8.5. Manufacturer Sales Price Methods.....	148
8.5.1. Medicaid and AMP-Based Federal Upper Limits	148
8.5.2. Average Sales Price (ASP).....	149

8.6. How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs	150
Chapter 9: Relationships with Pharmaceutical Wholesalers	152
9.1. Wholesale Suppliers to Pharmacies	152
9.1.1. Largest Companies	152
9.1.2. Full-Line Wholesalers	153
9.1.3. Specialty Distributors	154
9.2. Wholesalers' Channel Role for Pharmacies	155
9.2.1. Physical Distribution	155
9.2.2. Financial Intermediation	156
9.2.3. Cost-Minus Pricing of Brand-Name Drugs to Pharmacies	157
9.2.4. Influence on Pharmacy Reimbursement.....	159
9.3. Relationships with Independent Drugstores	159
9.3.1. Wholesaler Services for Independent Pharmacies	160
9.3.2. Wholesaler Relationships with Pharmacy Buying Groups	163
9.3.3. Wholesaler Generic Programs for Retail Pharmacies	164
9.4. Large Retail Chains and Mail Pharmacies	165
9.4.1. Wholesale Suppliers to Largest U.S. Pharmacies.....	165
9.4.2. Changing Distribution Relationships Between Wholesalers and Retail Chains	166
9.4.3. Changing Generic Sourcing Relationships Between Wholesalers and Large Pharmacies	168
9.5. Wholesaler Relationships with the Three Largest Drugstore Chains.....	170
9.5.1. Walgreens-AmerisourceBergen Relationship	170
9.5.2. CVS Health-Cardinal Health Relationship	172
9.5.3. Rite Aid-McKesson Relationship	173
9.6. Wholesalers' Role in Pharmacy-Dispensed Specialty Drug Distribution.....	174
9.6.1. Specialty Products with Limited Pharmacy Networks	175
9.6.2. Specialty Products in Open Distribution	176
Chapter 10: Pharmacy and Prescription Profitability	178
10.1. Overall Drugstore Gross Margins	178
10.1.1. Industry Averages	178
10.1.2. Large Chain Drugstores	180

10.2. Pharmacy Per-Prescription Profits	180
10.2.1. Sources of Per-Prescription Profits	180
10.2.2. Average Prescription Gross Margins	182
10.2.3. PBM Per-Prescription Profits from Network and Mail Pharmacies	184
10.2.4. Pharmacy Profits with Acquisition Cost-Based Reimbursement	185
10.3. Profitability for Generic Prescriptions.....	186
10.3.1. Lifecycle Profits for Generic Drugs.....	186
10.3.2. Retail Generic Drug Discount Programs.....	190
10.3.3. The Impact of Generic Price Inflation	192
10.4. Pharmacy Profits from the 340B Drug Pricing Program	193
10.4.1. Overview of the 340B Program.....	193
10.4.2. The Role and Identity of 340B Contract Pharmacies	194
10.4.3. Flow of Funds with a Contract Pharmacy	195
10.4.4. Pharmacy and Covered Entity Profits from 340B Prescriptions	196
Acronyms and Abbreviations	198
Endnotes	199

LIST OF EXHIBITS

Exhibit 1: Top 10 Traditional Therapy Categories and Average Prescription Cost, 2014	4
Exhibit 2: Timeline of DSCSA Requirements for Pharmacies (Dispensers)	5
Exhibit 3: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2015	9
Exhibit 4: Average Annual Prescription Revenue per Pharmacy Outlet, 2015	9
Exhibit 5: Average Wait Time for Prescription Pickup and Pharmacist Consultation, by Dispensing Format, 2014 ...	10
Exhibit 6: Customer Satisfaction with Pharmacies, by Dispensing Format, 2015.....	10
Exhibit 7: Top Three Reasons for Pharmacy Selection, by Dispensing Format, 2014	11
Exhibit 8: Pharmacist Employment and Salary, by Dispensing Format, 2014	12
Exhibit 9: Pharmacist Employment, by Dispensing Format, 2014 vs. 2024	13
Exhibit 10: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2015	16
Exhibit 11: Outpatient Prescriptions, Annual Total and Growth, 2010-2015E	17
Exhibit 12: 30-Day Equivalent Outpatient Prescriptions, Annual Total and Growth, 2010-2015E	17
Exhibit 13: 90-Day Prescriptions as a Percentage of Total Prescriptions, by Dispensing Format, 2010 vs. 2015E	18
Exhibit 14: Pharmacy Industry Revenues, Annual Total and Growth, 2010-2015E	19
Exhibit 15: Largest 15 U.S. Pharmacies Ranked by Total Prescription Revenues, 2015	20
Exhibit 16: Share of Revenue Growth, by Dispensing Pharmacy Format, 2010 vs. 2015E	21
Exhibit 17: Total Change in 30-Day Equivalent Prescriptions Dispensed, by Pharmacy Format, 2010-2015E	22
Exhibit 18: Number of Pharmacies, by Dispensing Format, 2010 vs. 2015	23
Exhibit 19: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2014 vs. 2015E	23
Exhibit 20: Prescription Revenues, by Dispensing Format, 2014 vs. 2015E	24
Exhibit 21: Year-Over-Year Change in Same-Store Prescription Count, 2012-2015	25
Exhibit 22: Top 10 Regional Chain Drugstores, by Total Prescription Revenues, 2014	28
Exhibit 23: Number of Independent Pharmacies, 1990-2015	30
Exhibit 24: Mail Prescriptions, Annual Total and Growth, 2003-2015E.....	31
Exhibit 25: Share of Mail Pharmacy Revenues, by Company, 2015	34
Exhibit 26: Number of U.S. Retail Clinics, 2004-2017	35
Exhibit 27: Location of Retail Clinics, by Chain, 2015	36
Exhibit 28: Providers of Medication Therapy Management Services, Medicare Part D, 2015.....	39
Exhibit 29: Adult Influenza Vaccination, by Place of Vaccination, 2012-13 vs. 2015-16 Seasons	40
Exhibit 30: Factors Determining Health Plan Classification as Specialty Therapy, 2011 vs. 2014	43
Exhibit 31: Top 10 Specialty Therapy Categories and Average Prescription Cost, 2014	44
Exhibit 32: Specialty Drug Approvals, 2005 to 2015	45
Exhibit 33: Specialty Drugs as a Percentage of Pharmacy Benefit Spending, by PBM, 2011-2014	46
Exhibit 34: Number of Pharmacy Locations with Specialty Pharmacy Accreditation, URAC vs. ACHC, January 2016	50
Exhibit 35: Locations with URAC Specialty Pharmacy Accreditation, 2008-2016.....	50

Exhibit 36: Examples of Pharmacies Dispensing Specialty Pharmaceuticals	51
Exhibit 37: Pharmacy Locations with Specialty Pharmacy Accreditation, by Corporate Ownership, January 2016 ...	51
Exhibit 38: Fastest-Growing Private Specialty Pharmacies, 2014.....	53
Exhibit 39: Acquisitions of Specialty Pharmacies by Retail Chains, 2012-2015	54
Exhibit 40: Oncology Volume, by Dispensing Channel, 2015	58
Exhibit 41: Pharmacy Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2015.....	59
Exhibit 42: Leading Specialty Hub Services Providers, 2015.....	64
Exhibit 43: Summary of Flows in the U.S. Distribution and Reimbursement System.....	67
Exhibit 44: Share of U.S. National Health Expenditures, by Major Spending Category, 1974-2024.....	69
Exhibit 45: Source of Payment for Outpatient Prescription Drug Expenditures, 2014.....	70
Exhibit 46: Outpatient Prescription Drugs as Share of U.S. National Health Expenditures, by Payer, 2014	71
Exhibit 47: Change in Net Spending for Outpatient Prescription Drugs, by Payer, 2013 vs. 2014	71
Exhibit 48: Consumers’ Out-of-Pocket Spending Share of Outpatient Prescription Drug Expenditures, 1973-2014..	73
Exhibit 49: Change in Gross Drug Spending, Traditional vs. Specialty Drugs, by PBM, 2014	74
Exhibit 50: Change in Gross Pharmacy Benefit Drug Spending, Traditional vs. Specialty Drugs, 2002 to 2014	75
Exhibit 51: Generics, Share of U.S. Prescriptions, 2003-2019	75
Exhibit 52: Top 10 U.S. Drugs, 2014 Actual vs. 2020 Forecast.....	76
Exhibit 53: Pharmacy Industry Revenues, Traditional vs. Specialty Drugs, 2010-2020	76
Exhibit 54: Projected Growth Rates in National Health and Outpatient Prescription Drug Expenditures, 2012-2024	77
Exhibit 55: Median Prescription Expenses per Person, by Age, 2013.....	78
Exhibit 56: Forecast Change in Gross Drug Spending, Traditional vs. Specialty Drugs, by PBM, 2015-2017.....	79
Exhibit 57: Source of Payment for Outpatient Prescription Drug Expenditures, 2024.....	80
Exhibit 58: Total Expenditures for Outpatient Prescription Drugs, by Payer, 2024.....	81
Exhibit 59: PBM Market Share, by Total Prescription Claims, 2015	83
Exhibit 60: Common Pharmacy Benefit Plan Designs.....	86
Exhibit 61: Prevalence of Utilization Management Tools to Manage Specialty Drug Costs, by Employer Size, 2015..	88
Exhibit 62: Rebates and Discounts as a Percentage of Pharmaceutical Manufacturers’ Brand-Name Gross Sales, 2007 to 2014.....	89
Exhibit 63: Price Increases for Brand-Name Drugs, Invoice vs. Net Price Growth, 2010-2014	90
Exhibit 64: Number of Products on PBM Formulary Exclusion Lists, 2012-2016.....	91
Exhibit 65: Formulary Exclusions for Specialty Drugs, Medicare Part D, 2016	93
Exhibit 66: PBM Rebate Arrangements for Traditional Brand Medications, Employer-Sponsored Plans, 2015	94
Exhibit 67: Government Programs, Average Rebates as Percentage of Retail Drug Price	95
Exhibit 68: Largest Pharmacy Services Administration Organizations, by Members and Ownership, 2015	97
Exhibit 69: Key Components of PBM Compensation	100
Exhibit 70: PBM Compensation Approach, by Employer Size, 2015.....	100

Exhibit 71: Distribution of Cost-Sharing Formulas for Prescription Drug Benefits in Employer-Sponsored Plans, 2005 vs. 2015.....	104
Exhibit 72: Average Copayments by Prescription Drug Tier, Employer-Sponsored Plans, 2005 vs. 2015.....	104
Exhibit 73: Cost-Sharing Arrangements for Prescription Drug Benefits in Employer-Sponsored Plans, 2015.....	105
Exhibit 74: Average Copayments by Prescription Drug Tier, Bronze vs. Platinum Health Insurance Marketplace Plans, 2015.....	106
Exhibit 75: Type of Cost-Sharing for Prescription Drug Benefits, Health Insurance Marketplace Plans, Platinum Plans, 2016.....	106
Exhibit 76: Type of Cost-Sharing for Prescription Drug Benefits, Health Insurance Marketplace Plans, Bronze Plans, 2016.....	107
Exhibit 77: Standard Medicare Prescription Drug Benefit, 2016.....	108
Exhibit 78: Median Copayments by Prescription Drug Tier, Medicare Part D Plans, 2015.....	109
Exhibit 79: Type of Cost-Sharing for Prescription Drug Benefits, Medicare Part D Prescription Drug Plans, 2015.....	109
Exhibit 80: Percentage of Employer-Sponsored Plans with Pharmacy Benefit Deductibles, 2012 to 2015.....	111
Exhibit 81: Percentage of Health Insurance Marketplace Plans with Separate Prescription Drug Deductible, 2016.....	112
Exhibit 82: Sources of Free Trial Vouchers, Coupons, and Copay Cards, 2014.....	113
Exhibit 83: Summary of Pharmacy Benefit Network Design Options.....	116
Exhibit 84: Medicare Part D PDPs with Preferred Pharmacy Networks, 2011-2016.....	119
Exhibit 85: Participation as Preferred Cost Sharing Pharmacies in Selected Medicare Part D PDPs, Retail Chain and Independent Pharmacies, 2016.....	121
Exhibit 86: Retail Pharmacy Network Design in Employer-Sponsored Plans, 2015.....	122
Exhibit 87: CVS Health, Maintenance Choice Covered Lives and Caremark Retail Channel Share, 2009 to 2015.....	123
Exhibit 88: Mail Pharmacy Network Design in Employer-Sponsored Plans, Maintenance Medications, 2015.....	124
Exhibit 89: DIR Fees for Medicare Part D Preferred Cost-Sharing Pharmacies, 2015.....	126
Exhibit 90: Share of Hepatitis C Virus (HCV) Drug Expenditures, by Dispensing Format, 2014.....	128
Exhibit 91: Payer-Mandated Usage of Specialty Pharmacies for Oncology Products, by Product Type, 2010-2014.....	129
Exhibit 92: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost (EAC).....	133
Exhibit 93: Average Dispensing Fee for Brand-Name Prescriptions at Retail Pharmacies, 1999 to 2015.....	133
Exhibit 94: Methodology Used to Compute Average Wholesale Price, by Publisher.....	137
Exhibit 95: Reimbursement of Brand-Name Prescriptions, Percentage of Average Wholesale Price, by Dispensing Format, 2015.....	138
Exhibit 96: Reimbursement of Specialty Drug Prescriptions at Specialty Pharmacies, Percentage of Average Wholesale Price, 2004 to 2014.....	138
Exhibit 97: Percentage of AWP Billed to Employers for Brand-Name Prescriptions, Retail vs. Mail, 1999 to 2015.....	139
Exhibit 98: Generic Drugs, Comparison of Per-Unit Pricing Metrics and Pharmacy Acquisition Cost, Medicaid.....	142
Exhibit 99: Reimbursement of Generic Prescriptions, Percentage of Average Wholesale Price and Copayment, by Dispensing Format, 2015.....	142

Exhibit 100: Acquisition Cost Methodologies for Pharmacy Reimbursement Used by State Medicaid Programs, 2015	147
Exhibit 101: Example of Brand-Name Prescription Economics for a Third-Party Payer	150
Exhibit 102: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, 2015	152
Exhibit 103: Full-Line Wholesaler Sales, by Type of Customer, 2014	154
Exhibit 104: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2014.....	154
Exhibit 105: Determination of a Pharmacy’s Brand-Name Drug Acquisition Cost from a Wholesaler	157
Exhibit 106: Estimated Market Share with Independent Pharmacies, by Wholesaler, 2014	160
Exhibit 107: U.S. Pharmacy Franchise and Marketing Programs of Large Drug Wholesalers, 2014	161
Exhibit 108: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationship, 2015	163
Exhibit 109: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers	165
Exhibit 110: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2014.....	167
Exhibit 111: Share of U.S. Generic Purchasing Volume, by Organization, 2015	169
Exhibit 112: Cardinal Health, Revenues from CVS Health and Walgreens, 2011-2015	173
Exhibit 113: Rite Aid, Total Inventories and Days Sales in Inventory, 2013 to 2015	174
Exhibit 114: Alternative Channels to Specialty Pharmacies in Limited Networks	176
Exhibit 115: Overall Gross Margins for Chain and Independent Drugstores, 1993-2013.....	179
Exhibit 116: Total Gross Profits for Chain and Independent Drugstores, 2003-2013.....	179
Exhibit 117: Overall Gross Margins for Drugstores, by Company, 2014.....	180
Exhibit 118: Example of Brand-Name Prescription Economics for a Pharmacy	181
Exhibit 119: Average Prescription Gross Margins at Independent Drugstores, 2006-2014	182
Exhibit 120: Diplomat Pharmacy, Per-Prescription Revenues and Profits, 2011-2015	183
Exhibit 121: Average Retail Pharmacy Gross Margin per Prescription, Brand-Name vs. Generic Drugs, 2012.....	184
Exhibit 122: PBM Gross Margin per Equivalent Script, by Channel and Drug Type, 2015.....	185
Exhibit 123: Lifecycle of Per-Prescription Gross Profits, Brand vs. Multisource Generic	187
Exhibit 124: Incremental Pharmacy Gross Profits from Newly Launched Generics, 2011-2016	188
Exhibit 125: Examples of Pharmacy Acquisition Cost, Brand-Name vs. Generic Drug, 2015	189
Exhibit 126: Number of Products on Retail Generic Discount Lists, by Retail Chain, 2012 vs. 2015	192
Exhibit 127: 340B Contract Pharmacy Locations, by Chain, 2015	194
Exhibit 128: Flow of Funds and Product for 340B Contract Pharmacy Network	195
Exhibit 129: Hypothetical Profits for a 340B Entity From a Third-Party Prescription Dispensed by a 340B Contract Pharmacy	197